Layoff rounds in the biopharma industry remain consistent across the first three quarters of 2025, with 190 rounds nearly matching 2024’s total of 192. Major companies such as Novo Nordisk and Merck announced significant workforce reductions—9,000 and 6,000 employees respectively—with Novo Nordisk’s cuts planned to save $1.3 billion annually by 2026 and Merck aiming for $3 billion savings by 2027. Sarepta Therapeutics also restructured, focusing on siRNA programs after a 36% staff reduction amid safety concerns over their gene therapy. These layoffs reflect ongoing strategic realignments within biopharma amidst market pressures.